These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]
8. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Forestier N; Zeuzem S Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis in 2010: the dawn of a new era in HCV therapy. Ciesek S; Manns MP Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):69-71. PubMed ID: 21293503 [TBL] [Abstract][Full Text] [Related]
10. [Chronic hepatitis C: improved cure rates with new approved medications]. Grammatikos G; Vermehren J; Zeuzem S MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428 [No Abstract] [Full Text] [Related]
11. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Poordad F; Lawitz E; Reddy KR; Afdhal NH; Hézode C; Zeuzem S; Lee SS; Calleja JL; Brown RS; Craxi A; Wedemeyer H; Nyberg L; Nelson DR; Rossaro L; Balart L; Morgan TR; Bacon BR; Flamm SL; Kowdley KV; Deng W; Koury KJ; Pedicone LD; Dutko FJ; Burroughs MH; Alves K; Wahl J; Brass CA; Albrecht JK; Sulkowski MS; Gastroenterology; 2013 Nov; 145(5):1035-1044.e5. PubMed ID: 23924660 [TBL] [Abstract][Full Text] [Related]
12. Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Kwo PY Liver Int; 2012 Feb; 32 Suppl 1():39-43. PubMed ID: 22212570 [TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C virus infection in 2013--quo vadis? Prelipcean CC; Mihai C Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):7-10. PubMed ID: 24505885 [No Abstract] [Full Text] [Related]
14. [Treatment of chronic hepatitis viral C: new associations]. Ouzan D Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659 [TBL] [Abstract][Full Text] [Related]
15. HCV, ribavirin, and anemia: a new dawn. Pol S Gastroenterology; 2013 Nov; 145(5):930-3. PubMed ID: 24060434 [No Abstract] [Full Text] [Related]
16. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients. Gholam PM N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682 [No Abstract] [Full Text] [Related]
17. The future for the treatment of genotype 4 chronic hepatitis C. Esmat G; El Raziky M; El Kassas M; Hassany M; Gamil ME Liver Int; 2012 Feb; 32 Suppl 1():146-50. PubMed ID: 22212586 [TBL] [Abstract][Full Text] [Related]
18. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?]. Song BC Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319 [No Abstract] [Full Text] [Related]
19. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. Cooper C; Lester R; Thorlund K; Druyts E; El Khoury AC; Yaya S; Mills EJ QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839 [TBL] [Abstract][Full Text] [Related]
20. What's new in HCV genotype 2 treatment. Mangia A; Mottola L Liver Int; 2012 Feb; 32 Suppl 1():135-40. PubMed ID: 22212584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]